Document is current
Any future updates will be listed below
-
Authors
Kostov, Aleksandar M. https://orcid.org/0009-0008-5034-8597
Jensen, Maj-Britt https://orcid.org/0000-0001-5348-3040
Ejlertsen, Bent https://orcid.org/0000-0001-8761-714X
Thomassen, Mads https://orcid.org/0000-0003-0078-1217
Rossing, Maria https://orcid.org/0000-0003-4325-3027
Pedersen, Inge S. https://orcid.org/0000-0002-9902-8040
Petersen, Annabeth H. https://orcid.org/0000-0002-4503-6942
Christensen, Lise Lotte https://orcid.org/0000-0001-5622-3068
Wadt, Karin A. W. https://orcid.org/0000-0003-2882-6798
Berrocal-Almanza, Luis C. https://orcid.org/0000-0003-1634-9971
Miranda, Miguel
Lænkholm, Anne-Vibeke https://orcid.org/0000-0003-2166-8686
-
Funding
Funding for this research was provided by:
Zealand Region
- License Information
-
More Information
Article History
Received: 13 February 2025
Accepted: 6 May 2025
First Online: 23 May 2025
Declarations
:
: AK and AL: Institutional grants from AstraZeneca. Personal grants (presentation): AstraZeneca; AVL: Advisory board: MSD, congress attendance support: Daiichi Sankyo, AstraZeneca; MJ: Meeting expenses and advisory board, Novartis; BE: institutional grants from AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, and Roche; grants for attending scientific meetings from MSD and Daiichi Sankyo; advisory board member organized by Eli Lilly and Medac. IP: Personal grant (presentation): AstraZeneca. KW: Personal grant (presentation), Seagen Denmark ApS. LCBA and MM are employees of AstraZeneca and hold shares; MT, CMR, and LL report no conflicts of interest.
: The study was approved by the board of the Danish Breast Cancer Cooperative Group, the Capital Region’s Center for Health (R-21061634), and the Zealand University Hospital’s Administration Board (EMN-2021–09331). The study is registered at the Capital Region Research Overview – PACTIUS (J.nr. P-2021–0729) and adheres to the General Data Protection Regulations.
